Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.(Source : 202003 Annual Report Page No:159)
Financial Results:
Aurobindo Pharma Ltd reported Revenues for Q4FY24 of ₹7,580.00 Crores up from ₹6,473.00 Crore year on year, a rise of 17.1%.
Total Expenses for Q4FY24 of ₹6,363.00 Crores up from ₹5,879.00 Crores year on year, a rise of 8.23%.
Consolidated Net Profit of ₹907.00 Crores up 79.25% from ₹506.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹15.51, up 79.51% from ₹8.64 in the same quarter of the previous year.
*It is important to note that the way the results have been accounted for are slightly different than the ones the companies may choose to publish.
*The presented data is automatically generated. It may occasionally generate incorrect information.